Neurocrine Biosciences, Inc. $NBIX Shares Sold by Generali Asset Management SPA SGR

Generali Asset Management SPA SGR lowered its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 13.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,703 shares of the company’s stock after selling 3,657 shares during the period. Generali Asset Management SPA SGR’s holdings in Neurocrine Biosciences were worth $3,220,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of NBIX. USA Financial Formulas acquired a new position in Neurocrine Biosciences in the fourth quarter valued at $25,000. Geneos Wealth Management Inc. boosted its stake in shares of Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after buying an additional 135 shares during the period. Golden State Wealth Management LLC boosted its stake in shares of Neurocrine Biosciences by 120.5% during the third quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock worth $26,000 after buying an additional 100 shares during the period. Eastern Bank acquired a new stake in shares of Neurocrine Biosciences during the third quarter worth about $27,000. Finally, Quent Capital LLC purchased a new position in shares of Neurocrine Biosciences during the third quarter worth about $32,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences Trading Up 1.8%

NASDAQ NBIX opened at $152.25 on Friday. The stock has a market capitalization of $15.31 billion, a price-to-earnings ratio of 23.46, a PEG ratio of 1.29 and a beta of 0.34. The business’s 50 day moving average is $131.12 and its two-hundred day moving average is $137.85. Neurocrine Biosciences, Inc. has a 12-month low of $115.66 and a 12-month high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). Neurocrine Biosciences had a net margin of 21.55% and a return on equity of 19.79%. The business had revenue of $805.50 million during the quarter, compared to analysts’ expectations of $804.21 million. During the same quarter last year, the firm earned $1.69 earnings per share. The firm’s quarterly revenue was up 28.3% compared to the same quarter last year. Equities analysts forecast that Neurocrine Biosciences, Inc. will post 6.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NBIX has been the subject of several analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $185.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, April 6th. HC Wainwright lifted their target price on Neurocrine Biosciences from $192.00 to $215.00 and gave the company a “buy” rating in a research note on Tuesday, April 7th. Zacks Research raised Neurocrine Biosciences from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 15th. Citigroup upped their price target on Neurocrine Biosciences from $242.00 to $246.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, BMO Capital Markets decreased their price target on Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating for the company in a report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and an average target price of $184.15.

Trending Headlines about Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: JPMorgan raised its price target on Neurocrine Biosciences to $185 from $177 and kept an overweight rating, signaling continued confidence in upside potential. Article link
• Positive Sentiment: Truist Financial lifted its price target to $155 from $140 and reiterated a buy rating, adding to the recent analyst support. Article link
• Positive Sentiment: Multiple firms, including Morgan Stanley, Guggenheim, Piper Sandler and Wedbush, issued upbeat views on NBIX, suggesting broad Wall Street optimism around the stock’s outlook. Article link
• Positive Sentiment: Neurocrine’s latest earnings beat helped reassure investors that the company’s core business remains on track, even if some analysts are still refining their models after the report. Article link
• Neutral Sentiment: A Seeking Alpha article argued that the core business is holding up, while noting the Soleno deal could add upside but also introduces risk. Article link

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.